Live price temporarily unavailable.
iSpecimen (ISPC) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $8.18M | $11.1M | $10.4M | $9.93M | $9.29M | $1.93M |
| Growth (year over year) | — | +36.1% | −6.6% | −4.6% | −6.4% | −79.2% |
| Gross profit | $4.60M | $5.89M | $5.65M | $5.16M | $4.18M | $215.7K |
| Gross margin | 56.2% | 52.9% | 54.3% | 51.9% | 45.0% | 11.2% |
| Operating income | −$2.41M | −$5.93M | −$10.2M | −$11.2M | −$12.7M | −$8.98M |
| Operating margin | −29.4% | −53.2% | −97.9% | −112.5% | −137.0% | −465.4% |
| Net income | −$4.65M | −$8.96M | −$10.2M | −$11.1M | −$12.5M | −$10.5M |
| Net margin | −56.8% | −80.5% | −98.5% | −111.8% | −134.5% | −543.7% |
| EPS (diluted) | −$3976.00 | −$1672.00 | −$928.00 | −$982.00 | −$703.20 | −$91.20 |
| Balance sheet | ||||||
| Cash and equivalents | $695.9K | $27.7M | $15.3M | $2.34M | $1.88M | $6.88M |
| Total assets | $6.21M | $35.7M | $24.6M | $15.8M | $9.35M | $9.53M |
| Total liabilities | $22.3M | $5.93M | $4.31M | $6.08M | $6.04M | $6.44M |
| Long-term debt | — | $3.42M | — | — | — | — |
| Shareholders' equity | −$27.3M | $29.8M | $20.3M | $9.74M | $3.31M | $3.09M |
| Cash flow | ||||||
| Operating cash flow | −$288.4K | −$10.7M | −$5.82M | −$5.81M | −$8.26M | −$4.24M |
| Capital expenditure | $426 | $2.55K | $215.5K | $19.5K | $31.5K | $454 |
| Free cash flow | −$288.8K | −$10.7M | −$6.03M | −$5.83M | −$8.30M | −$4.24M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.66M | $1.48M | $1.06M | $713.1K | $106.6K | — | $156.0K | $151.9K |
| Growth (year over year) | −4.2% | −42.7% | −53.8% | −75.1% | −96.0% | — | −85.2% | −78.7% |
| Gross profit | $1.11M | $295.0K | $448.1K | $269.0K | −$98.0K | — | $71.6K | $68.7K |
| Gross margin | 41.6% | 20.0% | 42.4% | 37.7% | −91.9% | — | 45.9% | 45.2% |
| Operating income | −$1.71M | −$5.84M | −$1.64M | −$1.82M | −$2.83M | — | −$2.54M | −$1.36M |
| Operating margin | −64.1% | −395.8% | −154.9% | −255.4% | −2655.2% | — | −1627.1% | −897.1% |
| Net income | −$1.44M | −$6.05M | −$1.66M | −$1.05M | −$2.78M | — | −$2.28M | −$1.36M |
| Net margin | −54.1% | −409.8% | −156.8% | −146.9% | −2608.7% | — | −1458.4% | −896.9% |
| EPS (diluted) | −$84.00 | −$216.00 | −$28.55 | −$16.78 | −$19.20 | — | −$6.66 | −$0.98 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.75M | $1.88M | $782.6K | $588.8K | $2.78M | $6.88M | $2.82M | $4.41M |
| Total assets | $11.3M | $9.35M | $6.84M | $6.03M | $9.00M | $9.53M | $6.61M | $7.39M |
| Total liabilities | $6.55M | $6.04M | $5.17M | $5.41M | $5.92M | $6.44M | $5.80M | $5.66M |
| Shareholders' equity | $4.71M | $3.31M | $1.67M | $622.0K | $3.07M | $3.09M | $814.0K | $1.74M |
| Cash flow | ||||||||
| Operating cash flow | −$1.08M | −$3.57M | −$1.10M | −$192.2K | −$2.04M | — | −$3.36M | −$689.6K |
| Capital expenditure | $14.5K | $7.87K | — | — | $0 | — | — | — |
| Free cash flow | −$1.09M | −$3.58M | — | — | −$2.04M | — | — | — |
| Share buybacks | $0 | — | — | — | — | — | — | — |
From iSpecimen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning iSpecimen in our feed yet.